Pharmacological profile of SSRIs and SNRIs in the treatment of eating disorders

Current Clinical Pharmacology

Volumn 4, Issue 1, 2009, Pages 78-83

  Capasso, Anna ^a   Petrella, Claudio ^b   Milano, Walter ^b  

^a UNIVERSITY OF SALERNO   (Italy)

^b ASL NA 1   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; ADRENERGIC RECEPTOR AFFECTING AGENT;

BINGE EATING DISORDER; BULIMIA; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EATING DISORDER; EATING HABIT; FOOD PREFERENCE; HUMAN; NAUSEA; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT CONTROL; XEROSTOMIA; COMPARATIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC UPTAKE INHIBITORS; BULIMIA NERVOSA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 65549143665     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488409787236092     Document Type: Review

References (66)

1. Wilfley D.E.; Rieger E. Further Perspectives on Psychological Interventions for Eating Disorders. In: Maj M., Halmi K., Lòpez-Ibor J.J., Sartorius N. (eds.) Volume 6. Eating Disorders. WPA Series "Evidence and Experience in Psychiatry" 2002.
2. Walsh, JME.; Wheat ME.; Freund, K.; Detection, evaluation, and treatment of eating disorders. Journal of General Internal Medicine, 2000, 15 (8), 577-590
3. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, 4th, American Psychiatric Association, 1994.
4. Becker AE.; Grinspoon SK.; Klibanski A.; Herzog DB.; Eating disorders. New England Journal of Medicine, 1999; 340, 1092-1098.
5. Hoek HW.; van Hoeken D.; Katzman MA.; Epidemiology and cultural aspects of eating disorders: a review. In: Maj M., Halmi K., Lòpez-Ibor J.J., Sartorius N. (eds.) Volume 6. Eating Disorders. WPA Series "Evidence and Experience in Psychiatry" 2002.
6. Brewerton TD. Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology. 1995; 20, 561-590.
7. Agras WS. Pharmacotherapy of bulimia nervosa and binge eating disorder: longer-term outcomes Psychopharmacology Bulletin, 1997, 33, 433-436.
8. Kaye WH.; Frank GK.; Bailer UF.; Henry SE.; Meltzer CC.; Price JC.; Mathis CA.; Wagner A. Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies Physiol Behav, 2005; 85 (1), 73-81.
9. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998, 51, 215-235.
10. Klump KL; Kaye WH; Strober M.The evolving genetic foundations of eating disorders. Psychiatr Clin North Am, 2001, 24 (2), 215-225.
11. Devane CL. Comparative safety and tolerability of SSRI. Hum Psychopharmacol. 1995, 10, 185-193.
12. Henderson M.; Freeman CP. A self-rating scale for bulimia: the BITE. Br J Psychiatry. 1987, 150, 18-24.
13. American Psychiatric Association. Practice guideline for the treatment of patients with eating disorders. Am J Psychiatry. 2000, 157 (suppl):1.
14. Kaye, W.; Gendall, K.; Strober, M. Serotonin neuronal function and selective serotonin reuptake inhibitors treatment in anorexia and bulimia nervosa. Biol Psychiatry. 1998; 44, 825-838.
15. Brosen K.; Skjelbo E.; Rasmussen, BB.; Poulsen, HE.; Loft, S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 1993; 45, 1211-1214.
16. Bertschy G.; Vandel S, Allers G, Fluvoxamine-tricyclic antidepressant interactions. Eur J Clin Pharmacol. 1991, 40, 119-120.
17. De Vries, MH.; Raghoebar, M.; Mathlener IS.; van Harten, J. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit. 1992, 14, 493-498.
18. Fleishaker, J.; Hulst L. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol. 1994; 46, 35-39.
19. Overmars, H.; Scherpenisse, P.; Post, L. Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet. 1983, 8, 269-280.
20. Spigset, O.; Gramberg, K.; Hagg, S.; Soderstrom, E.; Dahlqvist, R. Non-linear fluvoxamine disposition. Br J Clin Pharmacol. 1998, 45, 257-263.
21. Strauss, WL.; Layton, ME.; Duger, SR. Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. Am J Psychiatry. 1998, 155, 380-384.
22. Walczak, DD.; Apter, JT.; Halikas, JA. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry. 1996, 8, 139-151.
23. Bruch, H., Psychotherapy in eating disorders Journal of the Canadian Psychiatric Association, 1977, 22, 102-110.
24. Walsh, T.; Devlin, M. Eating disorders: progress and problems Science. 1998, 280, 1387-1390.
25. Walsh, BT. Binge eating in bulimia nervosa. In: Fairburn CG, Wilson GT, eds. Binge Eating: Nature, Assessment and Treatment. New York, NY: Guilford Press, 1993.
26. Stunkard, AJ. Some perspectives on human obesity: its causes. Bull N Y Acad Med. 1988, 64, 902-911.
27. Stunkard, AJ. Binge eating disorder and the treatment of obesity Obese Res. 1991, 2, 279-283.
28. Yanoski, SZ.; Nelson, JE.; Dubbert, B.; Spitzer, RL. Binge eating disorder is associated with psychiatric comorbidity in the obese. Am J Psychiatry. 1993, 150, 1472-79.
29. Stuart, RR. Behavioural control of overeating. Behav Res Ther. 1967, 5, 357-64.
30. Ricca, V.; Mannucci, E.; Di Bernardo M. Disturbo da Alimentazione Incontrollata Binge Eating Disorder. Giornale Italiano di Psicopatologia. 1998, 2, 223-239.
31. Jimerson, DC.; Wolfe, BE.; Metzger, ED.; Finkelstein, DM.; Cooper, TB.; Levine, JM. Decreased serotonin function in bulimia nervosa. Arch Gen Psychiatry. 1997, 54, 529-534.
32. Spitzer, RL.; Yanovski, S.; Wadden, T.; Wing, R.; Marcus, MD.; Stunkard, A.; Devlin, M.; Mitchell, J.; Hasin, D.; Horne, RL. International Journal of Eating Disorders, 1993, 13, 137-153.
33. Kay WH. Serotonin regulation in bulimia. In: Hudson J, Pope H Jr, eds. The Psychobiology of Bulimia. Washington, DC: APA Press; 1987.
34. Buckett, WR.; Thomas, PG.; Luscombe, GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation Prog Neuropsychopharmacol Biol Psychiatry. 1988, 12, 575-584.
35. Stricker-Krongrad, A.; Souquet, AM.; Burlet, C. Effects of sibutramine on feeding behaviour in dietary-induced obesity role of dietary constituents Int J Obes. 1995, 19, P399.
36. Bray, GA.; Blackburn, GL.; Ferguson, JM. Sibutramine produces dose-related weight loss. Obes Res. 1999, 7, 189-198.
37. Cole, JO.; Kaiser, PE.; DeHaan, HA. Sibutramine hydrochloride: evaluation of abuse potential. Obes Res. 1991, 2, 145-150.
38. Weintraub, M.; Rubio, A.; Golik, A.; Byrne, L.; Scheinbum, ML. Sibutramine in weight control: a dose-ranging efficacy study Clin Pharmacol Ther. 1991, 50, 330-337.
39. Nisoli, E.; Carruba, M. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action Obes Rev. 2000, 1, 127-139.
40. Buckett, WR.; Thomas, PC.; Luscombe, GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic downregulation. Prog Neuropsychopharmacol Biol Psychiatry. 1988, 12, 575-584.
41. Gundlah, C.; Martin, KF.; Heal, DJ.; Auerbach, SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther. 1997, 283, 581-591.
42. Stricker-Krograd, A.; Burlet, C.; Souqurt, AM. Effects of sibutramine on feeding behaviour in dietary-induced obesity: a role of dietary components, Int J Obes. 1995, 19 (suppl 12), 145.
43. Kaiser, PE.; Hinson, JL. Sibutramine: dose response and plasma metabolic concentrations in weight loss. J Clin Pharmacol. 1994, 34, 1019-1023.
44. Van Gaal, LF.; Wauters, MA.; De Leew, IH. Anti-obesity drugs, what does sibutramine offer? An analysis of its potential contribution of obesity treatment Exp Clin Endocrinol Diabetes. 1998, 106, 35-40.
45. Hay, P.J.; Bacaltchuk, J. Psychological interventions for eating disorders: much done, much to be done. In: Maj M., Halmi K., Lòpez-Ibor J.J., Sartorius N. (eds.) Volume 6. Eating Disorders. WPA Series "Evidence and Experience in Psychiatry" 2002.
46. van Furth, E.F. Efficacy, effectiveness and the implementation of evidence. In: Maj M., Halmi K., Lòpez-Ibor J.J., Sartorius N. (eds.) Volume 6. Eating Disorders. WPA Series "Evidence and Experience in Psychiatry" 2002.
47. Crow, SC.; Praus, B.; Thuras, P. Mortality from eating disorders--A 5- to 10-year record linkage study. International Journal of Eating Disorders, 1999, 26, 97-101.
48. Lask, B.; Bryant-Waugh, R. Anorexia Nervosa and Related Eating Disorders in Childhood and Adolescence. Hove: Psychology Press (eds), 2000.
49. Costin, C. The Eating Disorder Sourcebook. Linconwood: Lowell House. 6, 1999.
50. Gowers, S.; Bryant-Waugh, R. Management of child and adolescent eating disorders: the current evidence base and future directions. J Child Psychol Psychiatry, 2004, 45 (1), 63-83.
51. Katzman, DK. Medical complications in adolescents with anorexia nervosa: a review of the literature. International Journal of Eating Disorders, 2005, 37 (Suppl.), S52-9.
52. Guidano, V.F. Complexity of the self, New York, Guilford Press, 1987.
53. Guidano, V.F. Self in process, New York, Guilford Press, 1991.
54. Steinhausen, H.C. The outcome of anorexia nervosa in the 20th century. American Journal of Psychiatry, 2002, 159, 1284-1293.
55. Birmingham, CL.; Su, J.; Hlynsky, JA.; Goldner, EM.; Gao, M. The mortality rate from anorexia nervosa. International Journal of Eating Disorders, 2005, 38 (2), 143-146.
56. Legroux-Gerot, I.; Vignau, J.; Collier, F.; Cortet, B. Bone loss associated with anorexia nervosa. Joint Bone Spine, 2005, 72 (6), 489-495.
57. Palazidou, E.; Robinson, P.; Lishman, WA. Neuroradiological and neuropsychological assessment in anorexia nervosa. Psychol Med, 1990, 20 (3), 521-527.
58. Lask, B.; Gordon, I.; Christie, D.; Frampton, I.; Chowdhury, U.; Watkins, B. Functional neuroimaging in early-onset anorexia nervosa. Int J Eat Disord, 2005, 37 (Suppl) S49.
59. Tiggemann, M.; Pickering, AS. Role of television in adolescent women's body dissatisfaction and drive for thinness. Int J Eat Disord, 1996, 20 (2), 199-203.
60. Klump, KL.; Kaye, WH.; Strober, M. The evolving genetic foundations of eating disorders. Psychiatr Clin North Am, 2001, 24 (2), 215-225.
61. Wade, TD.; Bulik, CM.; Neale, M.; Kendler KS. Anorexia nervosa and major depression: shared genetic and environmental risk factors Am J Psychiatry, 2000; 157 (3): 469-471.
62. Siegfried, Z.; Berry, EM.; Hao, S.; Avraham,Y. Animal models in the investigation of anorexia. Physiol Behav, 2003, 79 (1), 39-45.
63. Kaye, WH.; Frank, GK.; Bailer, UF.; Henry, SE.; Meltzer, CC.; Price, JC.; Mathis, CA.; Wagner, A. Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies Physiol Behav, 2005, 85 (1), 73-81.
64. Kaye, WH.; Bailer, UF.; Frank, GK.; Wagner, A.; Henry, SE. Brain imaging of serotonin after recovery from anorexia and bulimia nervosa. Physiol Behav, 2005, 86(1-2), 15-7.
65. Fetissov SO.; Harro J.; Jaanisk M.; Jarv A.; Podar I.; Allik J.; Nilsson I.; Sakthivel P.; Lefvert AK.; Hokfelt T. Autoantibodies against neuropeptides are associated with psychological traits in eating disorders Proc Natl Acad Sci U S A, 2005, 102 (41), 14865-70.
66. Lock, J.; Le Grange, D. Family-based treatment of eating disorders Int J Eat Disord, 2005, 37 (Suppl), S64-7.